Revenue
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Assembly Biosciences, Inc. (ASMB)
Price$36.10Cached quote
Net income
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $72.3M | $28.5M | $7.2M | $0 | $6.3M | $79.1M | $16.0M | $14.8M | $9.0M | $0 | — | — | — | — | — | — | — | — | — |
| Research & development | $64.8M | $55.9M | $48.9M | $70.0M | $68.5M | $106.8M | $85.8M | $72.7M | $44.2M | $33.1M | $18.4M | $10.7M | $15.0M | $19.5M | $25.3M | $1.9M | $2.9M | — | — |
| Operating expenses | $84.4M | $73.9M | $71.8M | $94.1M | $138.9M | $143.9M | $118.7M | $107.5M | $61.2M | $45.3M | $29.7M | $24.0M | $19.6M | — | — | — | — | — | — |
| Operating income | −$12.1M | −$45.4M | −$64.6M | −$94.1M | −$132.7M | −$64.8M | −$102.7M | −$92.7M | −$52.2M | −$45.3M | −$29.7M | −$24.0M | −$19.6M | −$24.9M | −$34.0M | −$4.8M | −$3.3M | — | — |
| Operating margin | −16.76% | −159.26% | −902.50% | — | −2,121.65% | −81.89% | −643.44% | −626.42% | −579.08% | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −$12.0M | −$45.3M | −$64.2M | −$93.6M | −$132.2M | −$64.1M | −$102.2M | −$92.1M | −$52.0M | −$45.2M | −$29.6M | −$23.9M | −$19.6M | −$24.9M | −$34.0M | −$4.8M | −$3.3M | — | — |
| EBITDA margin | −16.58% | −158.80% | −896.22% | — | −2,114.20% | −81.01% | −640.35% | −622.08% | −576.65% | — | — | — | — | — | — | — | — | — | — |
| Net income | −$6.1M | −$40.2M | −$61.2M | −$93.1M | −$129.9M | −$62.2M | −$97.6M | −$90.8M | −$42.8M | −$44.3M | −$28.5M | −$23.8M | −$19.4M | −$24.8M | −$34.3M | −$15.3M | −$4.5M | −$8.8M | −$4.6M |
| Net profit margin | −8.47% | −140.87% | −854.78% | — | −2,076.35% | −78.57% | −611.63% | −613.02% | −474.65% | — | — | — | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$0.55 | -$6.69 | -$13.38 | -$23.08 | -$5,190.23 | -$3,027.63 | -$6,435.88 | -$6,885.70 | -$4,169.48 | -$4,446.29 | -$3,131.44 | -$5,882.26 | -$8,650.38 | -$16,781.73 | -$30,881.84 | -$213,404.78 | -$86,676.77 | — | — |
| Diluted EPSper diluted share | -$0.55 | -$6.69 | -$13.38 | -$23.08 | -$5,190.23 | -$3,027.63 | -$6,435.88 | -$6,885.70 | -$4,169.48 | -$4,446.29 | -$3,131.44 | -$5,882.26 | -$8,650.38 | -$16,781.73 | -$30,881.84 | -$213,404.78 | -$86,676.77 | — | — |
Owners
Reported shareholders
25.07%of listed shares
GILEAD SCIENCES, INC.4.98M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
GILEAD SCIENCES, INC. | 25.07%4.98M shares |
FARALLON CAPITAL MANAGEMENT, L.L.C. | 8.08%1.6M shares |
Paradigm Biocapital Advisors LP | 7.83%1.55M shares |
Commodore Capital LP | 7.13%1.42M shares |
RA CAPITAL MANAGEMENT, L.P. | 5.14%1.02M shares |
Jupiter Topco LLC | 4.28%849.31K shares |
BlackRock, Inc. | 3.86%766.82K shares |
Schornstein Alexander | ≈3.67%728.11K shares |
Parkman Healthcare Partners LLC | 3.63%721.18K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.82%558.94K shares |
Point72 Asset Management, L.P. | 2.32%460.59K shares |
Seven Fleet Capital Management LP | 2.18%433.15K shares |
MILLENNIUM MANAGEMENT LLC | 1.51%298.81K shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.41%280.42K shares |
Schonfeld Strategic Advisors LLC | 1.22%242.15K shares |
AMERIPRISE FINANCIAL INC | 1.16%230K shares |
DV EQUITIES, LLC | 1.14%226.42K shares |
Aberdeen Group plc | 1.04%207.05K shares |
Affinity Asset Advisors, LLC | 0.96%190K shares |
B Group, Inc. | 0.89%175.71K shares |
Percentages use 19.85M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 17, 2026Form 4 | Bjorkquist Jeanette MPFO and PAO | SellCommon Stock | 29 | $23.25 | $674.25 | 14.6K |
| Mar 30, 2026Form 4 | Bjorkquist Jeanette MPFO and PAO | SellCommon Stock | 16 | $27.49 | $439.84 | 11.1K |
| Mar 30, 2026Form 4 | Bjorkquist Jeanette MPFO and PAO | SellCommon Stock | 312 | $26.65 | $8.3K | 11.1K |
| Mar 30, 2026Form 4 | White Nicole SChief Manufacturing Officer | SellCommon Stock | 9 | $27.49 | $247.41 | 37.5K |
| Mar 30, 2026Form 4 | White Nicole SChief Manufacturing Officer | SellCommon Stock | 188 | $26.65 | $5.0K | 37.5K |